Allergan Aesthetics' flagship toxin showed unexpected strength in Q2, signaling market stabilization after years of pressure.
AbbVie reported that Botox sales beat estimates in Q2, marking a notable inflection after a prolonged period of market headwinds. The revival reflects several converging factors: stabilization of the U.S. aesthetic market after GLP-1 disruption, successful defense against Evolus' Jeuveau price compression, and renewed demand from practices managing post-weight-loss patients seeking facial rejuvenation.
The strength arrives as AbbVie pursues FDA approval for a new masseter indication—a move that could unlock an adjacent patient population and differentiate Botox from generic competitors. For practice owners, the data suggests toxin pricing may have found a floor, and that volume recovery is possible if patient acquisition strategies account for the GLP-1 demographic shift.
Botox sales beat estimates in Q2, signaling market stabilization after years of pressure.
The pending masseter approval, expected in 2026, represents a material upside catalyst that could shift competitive dynamics in the neurotoxin category.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
